IGF2BP2 and acute kidney injury: Inhibition of METTL3 obviously alleviates renal injury and inflammation through IGF2BP2-dependent mechanisms, which suggests that targeting METTL3 may be a promising therapeutic approach for acute kidney injury (AKI) (21).